Contract drugmaker Catalent shrinks as pandemic wanes
The New Jersey-based company has announced two large rounds of layoffs at its Bloomington plant within six months—400 workers last December and 150 this month.
The New Jersey-based company has announced two large rounds of layoffs at its Bloomington plant within six months—400 workers last December and 150 this month.
State lawmakers have earmarked $30 million in the 2023-2025 budget for an orthopedics-retention initiative.
An Indianapolis woman is suing Community Health Network after the hospital system mailed her test results to the wrong person and that person posted the information on Facebook.
In 2017, Donahue was part of a team that performed Indiana’s first intravaginal embryo culture with an FDA-approved device that allowed embryos to grow in a device inside the patient rather than in an incubator in a lab.
The initiative, which includes a study and recently received a $2.9 million grant from the National Institute on Minority Health and Health Disparities, will provide participants with healthy food, cooking classes and even cooking utensils to attempt to move the needle forward.
Officials of the two-year-old firm that provides professional services in the health care and life science industries expect the offering to raise up to $8 million.
A judge ruled that Indianapolis-based Lilly was liable for higher payments due to its behavior in making false statements to the Centers for Medicare and Medicaid Services about the prices it charged distributors for its drugs.
Senate Enrolled Act 8 is part of a sweeping effort this year by the Indiana General Assembly to bring down the cost of health care across the state, where prices are among the highest in the country.
The Bloomington-based maker of medical devices said the move is part of a new plan to strongly focus on product innovation.
Its new partner, Ascension St. Vincent, is building a four-story brain and spine hospital on its flagship campus on West 86th Street in Indianapolis, which will be largely staffed with physicians from Goodman Campbell.
A seven-year clinical trial concluded that NICO Corp.’s devices are safe and effective to treat intracerebral hemorrhage.
Fishers-based INCOG Biopharma Services Inc., one of the newest players in the $132 billion contract drug manufacturing industry, acts as a behind-the-scenes player for companies that need to get sterile injectable medicines to market in a hurry.
The expansion will bring Eli Lilly and Co.’s total investment in the project to $3.7 billion, the most the company has ever spent on a single manufacturing site.
BiomEdit LLC was set up last year by Greenfield-based Elanco Animal Health and Boston-based Ginkgo Bioworks to make everything from food to therapeutics for animals. It’s already raised $36.5 million in venture capital for its work.
GeniPhys has developed a material known as Collymer, a highly-purified form of collagen that can be used to replace tissue that is lost in wounds and also forms “stable, fibrillar collagen scaffolds” that can help rebuild lost tissue.
Patricia Martin, the group’s president and CEO since 2019, last month announced she would step down to examine opportunities in the private sector and urged industry leaders to take a fresh look at the organization.
The National Institutes of Health awarded the grant to the Indiana Clinical and Translational Sciences Institute, a partnership among Indiana University, Purdue University and University of Notre Dame.
Gail Boudreaux is president and CEO of Elevance Health. Before joining Elevance (formerly known as Anthem Inc.), she spent six years as CEO of United Healthcare. She was named one of Fortune Magazine’s Most Powerful Women in Business and was featured by Forbes as one of the 100 Most Powerful Women in the World. Additionally, […]
Recovery Force Health said it plans to use the new funding as growth capital to market its device to hospitals and introduce other products.
The Weinberg Center for Corporate Governance at the University of Delaware, a leading voice for responsible corporate leadership, has generally supported the elimination of staggered terms, saying they can lead to entrenched boards and management that fails to perform.